In Q1–Q3 2021, Russian manufacturers produced RUB 432.7 billion worth of pharmaceutical drugs (manufacturer’s prices, VAT included), up 20% from the same period in 2020. Notable, the growth rates remain high for the third year in a row. In physical terms, the production volume was 2.98 billion packages; the growth rate was -16%. If calculated in minimum dosage units (MDU), the growth rate was -5.7%, and the production volume was 57.5 billion MDUs.

Only 4.8% of Russian doctors agree with the existing legal system in the healthcare, according to a survey conducted by the RNC Pharma analyst firm and the Doktor Na Rabote (Doctor at Work) social media service for doctors. Nearly the same number of the respondents, 4.7%, believe that mistakes that caused harm to the life and health of the patient should lead to the suspension of the doctor’s license. Blacklisting was the least popular answer option, with only 3.2% supporting such a measure.

More than half of Russian doctors (51.8%) believe that the CME system in its current form is “a pure formality”, according to a survey conducted by the RNC Pharma analyst firm and the platform for doctors Medvestnik. The second most popular answer, chosen by 15.4% of the respondents, was “most of the courses are very general and with minimal value.” Another 7.6% of the study participants say that the content quality is “very low”, since there are a lot of inaccuracies obvious to a specialist.

Only 6.1% of Russian doctors often recommend homeopathic / release-active drugs to their patients, according to a survey conducted by the RNC Pharma analyst firm and the Doktor Na Rabote (Doctor at Work) social media service for doctors. This group, mainly represented by men aged 46 and above, included doctors of more than 30 specialties, with 40% of them therapists, pediatricians, and neurologists. Another 27% of the respondents say that “the type of the drug does not matter as long as it is clinically effective”. Thus, about 33% of the Russian doctors seem accepting of release-active drugs.

In January—August 2021, Russian manufacturers produced RUB 384.7 bln worth of pharmaceutical drugs (manufacturer’s prices, VAT included), up 23.2% from January—August 2020. In physical terms, the production volume amounts to 2.65 billion packages, with the growth rate of -14.7%. If calculated in minimum dosage units (MDU), the growth rate is -5%, and the production volume is 51.2 billion MDUs.